Advanced Solid Tumor Clinical Trials in Phoenix, Arizona

7 studies are recruiting for advanced solid tumor in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

2. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

3. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

   This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Locations

   76 in total

   Run by

   BioNTech SE

   See if you can join NCT07070232 on ClinicalTrials.gov

4. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #132, Phoenix, Arizona

   Locations

   15 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06974110 on ClinicalTrials.gov

5. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

6. Evaluate the Safety and Clinical Activity of HH2853

   This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Haihe Biopharma Co., Ltd.

   See if you can join NCT04390737 on ClinicalTrials.gov

7. A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

   This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Phoenix, Phoenix, Arizona

   Locations

   10 in total

   Run by

   TORL Biotherapeutics, LLC

   See if you can join NCT06005740 on ClinicalTrials.gov